DOCSLIB.ORG

Advances at the Interface Between Metabolism & Epigenetics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Advances at the Interface Between Metabolism & Epigenetics Advances at the interface between metabolism & epigenetics 16-17 January, 2019 Robinson College, Cambridge In partnership with Advances at the interface between metabolism & epigenetics Cambridge, January 16-17 2019 Our sponsors and exhibitors This conference is supported by the Cambridge Metabolic Network, working in partnership with the Babraham Institute, with additional funding from the following sponsors and exhibitors. 2 Advances at the interface between metabolism & epigenetics Cambridge, January 16-17 2019 CONTENTS A few practicalities 5 Optional sessions 5 Day 1 programme 6 Day 2 Programme 8 Link to conference abstracts 9 Contributor biographies 10 3 Full p sponsor ad— HMT 4 Advances at the interface between metabolism & epigenetics Cambridge, January 16-17 2019 A few practicalities Your badge… is from Blendology.com and uses patented OneTAP technology, making it easy to swap contact details with other conference participants. Tapping badges means that you agree to pass on your name, job title, affiliation and email address plus any other information you might have added to your profile. You can also use your badge to vote for your favourite poster during the conference. If you have any questions about your badge the reception team will be happy to help. Conference dinner… Selwyn College is just a short walk from Robinson College. When you get out onto Grange Road, just turn right and it’s 250m along, on the left. Tea and coffee will be available after the talks on day 1 for anyone who’d like to go straight from one venue to the next, or there’s a little time in case you’d prefer to return to your hotel to freshen up. If you’re not sure whether or not your ticket includes entrance to the conference dinner, please ask at the reception desk. Attendance certificates… we haven’t pre-printed these as we know that not everybody wants them and we don’t want to waste paper. If you would like one, please leave your name at the reception desk and we’ll be happy to provide one for you. We value your feedback… once the conference closes you’ll receive a request from us to complete a short online questionnaire. We’d really appreciate it if you take the time to fill it in as it’s important to us to understand your views and will give us useful information to report back to our funders. Wednesday 16th January, 13:25 Optional sessions Drugging Transcription: Progress and Potential for Treating Human Diseases - Cancer, Immunology & Metabolism (Auditorium). Rab Prinjha, VP Head of Epigenetics DPU for GSK, will talk about current research interests. No need to book. Meet the speaker (Auditorium Lounge) Prof Paulo Sassone-Corsi and Dr Sevin Turcan will be available for an informal chat over coffee. Places are limited, please book in advance. Thursday 17th January, 12:40 Alternatives to an academic career: why I took a different path (Auditorium) Do you know what you want to achieve in your career? Are you familiar with all the opportunities for someone with a research background? In the UK, just over half of new PhD graduates move out of higher education, taking their skills into the wider economy [What do researchers do? www.vitae.ac.uk]. 75% of those who remain aspire to an academic career but many are not aware of the breadth of opportunities open to them [Careers in Research Online Survey, www.vitae.ac.uk]. Our panel, Dr Rab Prinjha, VP Head of Epigenetics DPU for GSK, Dr Marc van der Schee, Head of Clinical at Owlstone Medical and Dr Daniel Ives, CEO of early stage start-up Shift Bioscience will offer insights based on their experience of research in non-academic settings. A great opportunity to put your questions to them. No need to book. Meet the speaker (Auditorium Lounge) Dr Andrew Pospisilik and Dr Erica Watson will be available for an informal chat over coffee. Places are limited, please book in advance. 5 Advances at the interface between metabolism & epigenetics Cambridge, January 16-17 2019 Programme, day 1 - Wednesday 16th January 2019 08:45 Registration opens Dining hall balcony, dining hall Exhibition; refreshments 09:30 Prof Patrick Maxwell Welcome & introduction Auditorium Regius Professor of Physic & Head of the School of Clinical Medicine, University of Cambridge SESSION 1 Epigenetic responses to metabolic and environmental changes Auditorium Session chair: Prof Brian Huntly 09:40 Prof Paolo Sassone-Corsi KEYNOTE Donald Bren Professor & Director of the The epigenetic language of circadian metabolism Center for Epigenetics & Metabolism, University of California, Irvine 10:40 Prof Jane Mellor Deconstructing the relationship between Department of Biochemistry, metabolism, chromatin & gene expression in the University of Oxford yeast metabolic cycle 11:10 Break for refreshments Dining hall Exhibition 11:45 Prof Andrew Pospisilik Epigenetic contributions to metabolic disease Max Planck Institute of Immunobiology & heterogeneity Epigenetics, Freiburg & Van Andel Research Institute, Grand Rapids 12:15 Dr Marcus Buschbeck Histone variants link metabolism to 3D chromatin Josep Carreras Leukaemia Research Institute, architecture Barcelona 12:30 Poster previews Auditorium Elena Stoyanova Deciphering a metabolism-sensitive readout of Babraham Institute, Cambridge histone crotonylation Dr Philip Bland MLL3 mutations overcome glycolytic stress in Institute of Cancer Research, London breast cancer by utilising the pentose phosphate pathway Matthew Sinton Intracellular lipid accumulation in hepatocytes University of Edinburgh leads to dysregulation of the TCA cycle & a global increase in 5-hydroxymethylcytosine Dr Simone Ecker Epigenetics of exceptional longevity UCL Cancer Institute, London 6 Advances at the interface between metabolism & epigenetics Cambridge, January 16-17 2019 Cont... 12:45 Break for lunch Exhibition; ‘Meet the speaker’ tables Dining hall; Auditorium lounge 13:25 Optional session: Dr Rab Prinjha Drugging Transcription: Progress and Potential for VP Head of Epigenetics DPU, GSK Treating Human Diseases- Cancer, Immunology & Metabolism Auditorium 13:45 Poster session opens Browse abstracts at www.metabolism.ac.uk/EpiMetAbstracts Please cast your vote using your OneTAP badge Dining hall SESSION 2 Metabolic control of epigenetic pathways Auditorium Session chair: Dr Jason Locasale 15:10 Prof Wolfgang Fischle Lipid precursors & lipids in chromatin regulation King Abdullah University, Saudi Arabia 15:40 Dr Kathryn Wellen Acetyl-CoA metabolism in chromatin regulation Department of Cancer Biology, University of & tumorigenesis Pennsylvania 16:10 Mattia Zaghi SETD5, a new connection between epigenetic & Vita-Salute San Raffaele university mitochondrial function 16:25 Break for refreshments Exhibition Dining hall 17:00 Dr Thomas Carell Ludwig Maximilian University of Munich Metabolic control of Tet activity in the brain 17:30 Dr Andreas Ladurner Allosteric activation of a chromatin remodelling Ludwig Maximilian University of Munich oncogene by NAD metabolites You may either hold onto your OneTAP badge overnight or return it to us & collect it in the morning 18:45 Drinks reception & conference dinner Selwyn College, Grange Road, Cambridge 7 Advances at the interface between metabolism & epigenetics Cambridge, January 16-17 2019 Programme, day 2 - Thursday 17th January 2019 08:30 Registration desk opens Dining hall balcony, dining hall Refreshments 09:00 Dr Christian Frezza Welcome to day 2 Auditorium On behalf of the organisers SESSION 3 Physiological effects on the epigenome Auditorium Session chair: Prof Anne Ferguson-Smith 09:05 Dr Erica Watson How your grandparents’ sins affect your health Department of Physiology, Development & Neuroscience University of Cambridge 09:35 Dr Marika Charalambous Genomic imprinting - adiposity & pregnancy Department of Medical & Molecular Genetics, King’s College London 10:05 Dr Alice Taylor Methionine metabolism impacts maintenance of University of Cambridge AML with chromatin regulation 10:20 Break for refreshments Dining hall Exhibition 10:45 Prof Cecilia Lindgren Epigenomics of common obesity Big Data Institute, University of Oxford 11:15 Dr Olivia Casaneueva Variability in neuronal heat shock responses Babraham Institute, Cambridge causes heterogeneity in fat metabolism across individual worms 11.45 Dr Simona Pedrotti The histone methyltransferases Suv420h regulate PPAR-ɣ & energy expenditure in response to San Raffaele Hospital, Milan environmental stimuli 12:00 Break for lunch Dining Hall; Auditorium Lounge Exhibition; ‘Meet the speaker’ tables 12:40 Optional session: Dr Rab Prinjha, VP Head of Epigenetics DPU, GSK; Alternatives to an academic career: why I took a Dr Marc van der Schee, Owlstone Medical; different path Auditorium Dr Daniel Ives, Shift Bioscience 8 Advances at the interface between metabolism & epigenetics Cambridge, January 16-17 2019 Cont... SESSION 4 Metabolism and epigenetics in disease Auditorium Session chair: Dr Kathryn Wellen 13:25 Dr Judith Favier Uncoupled effects of TET inhibition & hypoxia in Research Director, Head of the Genetics and SDH-deficient cells Metabolism of Rare Cancers Laboratory, Inserm, Paris 13:55 Dr Sevin Turcan The impact of IDH1 mutation on the glioma Heidelberg University Hospital epigenome 14:25 Break for refreshments Exhibition Dining hall 14:50 Dr Jason Locasale Duke University, North Carolina Diet, cancer and epigenetics 15:20 Professor Brian Huntly Transcriptional & metabolic alterations during Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge leukaemia evolution 15:50 Professor Sir Stephen O’Rahilly Prizes
Load more

Recommended publications
  • Investigating the Heterogeneity of Glucose and Glutamine Metabolism in Cancer
    INVESTIGATING THE HETEROGENEITY OF GLUCOSE AND GLUTAMINE METABOLISM IN CANCER A Dissertation Presented to the Faculty of the Graduate School of Cornell University In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy by Ahmad Abdul Rahman Cluntun August 2017 © 2017 Ahmad Abdul Rahman Cluntun INVESTIGATING THE HETEROGENIETY OF GLUCOSE AND GLUTAMINE METABOLISM IN CANCER Ahmad Abdul Rahman Cluntun, Ph.D. Cornell University 2017 Rapidly proliferating cancer cells have increased biosynthetic and bioenergetic needs compared to quiescent cells. Hence, they undergo a reprogramming of intermediary metabolism, mainly by upregulating the uptake and catabolism of certain nutrients. The classical example of this is the ‘Warburg effect’ or aerobic glycolysis, defined as an increase in glucose uptake coupled to lactate secretion, regardless of oxygen availability in cancer cells. One consequence of this is that the majority of glucose carbon is diverted away from the mitochondria and the tricarboxylic acid (TCA) cycle, and secreted out of the cell as lactate. This prompts some cancer cells to exhibit an increased dependence on glutamine metabolism to refill the TCA cycle. However, recent studies have uncovered widespread heterogeneity on the roles of glucose and glutamine metabolism in cancer cells, prompting a need for further clarification. In order to examine these metabolic pathways in cancer cells, I first helped develop high- resolution LC-MS metabolomic workflows. The initial objective of my thesis focused on the Warburg effect, and specifically, the increased rate of glycolytic flux that occurs in colon cancer cells. I demonstrated that changes in glycolytic flux could modify specific histone acylation marks in a dose-dependent manner, suggesting that a possible function of the Warburg effect is to confer specific signaling effects on cancer cells.
    [Show full text]
  • NIH Public Access Author Manuscript Nat Rev Cancer
    NIH Public Access Author Manuscript Nat Rev Cancer. Author manuscript; available in PMC 2013 October 23. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Nat Rev Cancer. 2013 August ; 13(8): 572±583. doi:10.1038/nrc3557. Serine, glycine and the one-carbon cycle: cancer metabolism in full circle Jason W Locasale1,2,3,4,* 1Biochemistry and Molecular Cell Biology, Cornell University, Ithaca NY 14850 2Genomics, Genetics and Development, Cornell University, Ithaca NY 14850 3Tri-Institutional Program in Computational Biology and Medicine 4Divison of Nutritional Sciences, Cornell University, Ithaca NY 14850 Abstract One carbon metabolism involving the folate and methionine cycle integrates carbon units from amino acids, including serine and glycine, and generates diverse outputs, such as the biosynthesis of lipids, nucleotides and proteins, the maintenance of redox status, and the substrates for methylation reactions. Long considered a `housekeeping' process, this pathway has been recently shown to have additional complexity. Recent genetic and functional evidence also suggests that hyperactivation of this pathway is a possible driver of oncogenesis and establishes links to cellular epigenetic status. Given the wealth of clinically available agents that target one carbon metabolism, these new findings could present opportunities for translation into precision cancer medicine. *correspondence: [email protected]. Links Database of the human metabolic network:humanmetabolism.org Status of Cancer clinical trials in the United States: cancer.gov/clinicaltrials Encyclopedia of metabolic pathways: metacyc.org Human Metabolite Database: hmdb.ca Jason Locasale's website: Jlocasale.human.cornell.edu Metabolomics resources on behalf of Dr. Gary Siuzdak's lab: metlin.scripps.edu National Institutes of Health initiative on metabolomics: commonfund.nih.gov/Metabolomics/ Timeline 1944 ± Soldiers in the Pacific Islands with tropical anemia are treated with B vitamins.
    [Show full text]
  • Jason Locasale Web Bio
    Jason Locasale Web Bio Information Biography Biographical Statement Jason W. Locasale, Ph.D. is an Assistant Professor in the Division of Nutritional Sciences at Cornell University. He graduated from Rutgers University, Summa Cum Laude with a dual degree in Chemistry and Physics. He received his Ph.D. at the Massachusetts Institute of Technology in Biological Engineering. He then studied metabolism at Harvard Medical School where he worked as an American Cancer Society postdoctoral fellow and then later as an Instructor on the faculty. Dr. Locasale’s research focuses on understanding metabolism in cell growth, cancer pathogenesis and therapeutic intervention. His efforts have focused on understanding the Warburg Effect – the observation that tumor cells process glucose through fermentation even when oxygen is abundant for respiration. He has defined the mechanistic principles that lead to the Warburg Effect and is now investigating its downstream consequences on cellular physiology. He is currently translating this knowledge to develop biomarkers of agents that affect glucose metabolism in cancer. As a postdoctoral fellow, Dr. Locasale made the seminal discovery that a major pathway utilized by glucose-metabolizing cancer cells involved the diversion of glycolytic flux into one-carbon metabolism through de novo serine and glycine metabolism. Dr. Locasale is currently pursuing the role this pathway in disease pathogenesis and cell transformation and this work has led him to study the interplay between metabolism, signal transduction, and epigenetics. At the core of this effort lies the utilization of computational modeling and mass spectrometry-based metabolomics. Together this systems biology approach combines these tools with an integration of genetics, biochemistry, and cell biology.
    [Show full text]
  • 1 Environmental Factors Shape Methionine Metabolism in P16
    bioRxiv preprint doi: https://doi.org/10.1101/313288; this version posted May 2, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Environmental factors shape methionine metabolism in p16/MTAP deleted cells Sydney M. Sanderson1, Peter Mikhael1, Ziwei Dai1, and Jason W. Locasale1 1Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA Correspondence: Jason Locasale - [email protected] Abstract The co-deletion of a common tumor suppressor locus and neighboring metabolic gene is an attractive possible synthetic dependency of tumor suppression on metabolism. However, the general impact that these co-deletions have on metabolism, which also dependent on nutrient availability and the tissue of origin, is unknown. As a model to investigate this question, we considered a set of tissue-matched cancer cells with homozygous co-deletions in CDKN2a and MTAP, genes respectively encoding the most commonly deleted tumor suppressor p16 and an enzyme involved in methionine metabolism. A comparative metabolomics analysis revealed that while there exists a definite pan-cancer metabolic signature of MTAP-deletion, this signature was not preserved when cells were subjected to changes in the availability of methionine, serine, or cysteine, nutrients related to methionine metabolism. Notably, the heterogeneity exhibited by these cells in their responsiveness to nutrient availability dominated both MTAP status and tissue-of-origin. Furthermore, re-expression of MTAP exerted a modest effect on metabolism. Together these findings demonstrate that environmental factors, particularly nutrition and tissue identity, may overwhelm the genetic effects of collateral deletions of metabolic genes.
    [Show full text]
  • 1 Dietary Methionine Restriction Targets One Carbon Metabolism in Humans
    bioRxiv preprint doi: https://doi.org/10.1101/627364; this version posted May 4, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Dietary methionine restriction targets one carbon metabolism in humans and produces broad therapeutic responses in cancer Xia Gao1, Sydney M. Sanderson1¶, Ziwei Dai1¶, Michael A. Reid1, Daniel E. Cooper2, Min Lu3,4, John P. Richie Jr.5, Amy Ciccarella6, Ana Calcagnotto5, Peter G. Mikhael1, Samantha J. Mentch1, Juan Liu1, Gene Ables7, David G. Kirsch1,2, David S. Hsu3,4, Sailendra N. Nichenametla7, and Jason W. Locasale1* 1 Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA 2 Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA 3 Center for Genomics and Computational Biology, Duke University, Durham, NC 27710, USA 4 Department of Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA 5 Penn State University College of Medicine, Department of Public Health Sciences, Hershey, PA 17033, USA 6 Penn State University Clinical Research Center, State College, PA 16802, USA 7 Orentreich Foundation for the Advancement of Science, Cold Spring, NY 10516, USA ¶ Equal contribution * Correspondence: Jason Locasale – [email protected] Abstract Nutrition exerts profound effects on health and dietary interventions are commonly used to treat diseases of metabolic etiology. Although cancer has a substantial metabolic component, the principles that define whether nutrition may be used to influence tumour outcome are unclear. Nevertheless, it is established that targeting metabolic pathways with pharmacological agents or radiation can sometimes lead to controlled therapeutic outcomes.
    [Show full text]
  • I V Characterization of Gene-Environment Interactions
    Characterization of Gene-Environment Interactions That Govern Metabolic Adaptation by Sydney Morgan Sanderson Department of Pharmacology and Cancer Biology Duke University Date:_______________________ Approved: ___________________________ David MacAlpine, Supervisor ___________________________ Jason Locasale ___________________________ Christopher Newgard ___________________________ Matthew Hirschey ___________________________ Kris Wood Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Pharmacology and Cancer Biology in the Graduate School of Duke University 2019 i v ABSTRACT Characterization of Gene-Environment Interactions That Govern Metabolic Adaptation by Sydney Morgan Sanderson Department of Pharmacology and Cancer Biology Duke University Date:_______________________ Approved: ___________________________ David MacAlpine, Supervisor ___________________________ Jason Locasale ___________________________ Christopher Newgard ___________________________ Matthew Hirschey ___________________________ Kris Wood An abstract of a dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Pharmacology and Cancer Biology in the Graduate School of Duke University 2019 Copyright by Sydney Morgan Sanderson 2019 Abstract Metabolism is known to be driven by intrinsic genetic programs as well as contextual factors within the environment. Individual genetic and environmental determinants of metabolic state have
    [Show full text]
  • Diet, Sulfur Amino Acids, and Healthspan SYMPOSIUM 2015
    Diet, Sulfur Amino Acids, and Healthspan SYMPOSIUM 2015 Tarrytown House Estate & Conference Center Tarrytown, NY September 20-22, 2015 Orentreich Foundation for the Advancement of Science, Inc. To bring together scientists with an interest in diet and healthspan, to exchange knowledge, to generate ideas for future investigations, and to strengthen relationships within this community. 2 Diet, Sulfur Amino Acids, and Healthspan Tarrytown House Estate and Conference Center, Tarrytown, NY September 20-22, 2015 Schedule of Events Sunday, September 20, 2015 Cocktail Reception 6:00–6:30 pm Grand Salon, King Mansion Banquet Dinner 6:30–8:30 pm Library/Manor, King Mansion Welcome, David Orentreich, MD OFAS Keynote Address, Caleb Finch, PhD University of Southern California, Davis School of Gerontology 3 Diet, Sulfur Amino Acids, and Healthspan Tarrytown House Estate and Conference Center, Tarrytown, NY September 20-22, 2015 Monday, September 21, 2015 Symposium 8:15 am–5:00 pm Riverview Room, Atrium Morning Session, moderator: Jay Zimmerman, OFAS 8:15–8:30 Welcome – Jay Zimmerman 8:30–9:00 Gene Ables, OFAS 9:00–9:30 John Richie, Penn State University 9:30–10:00 Joseph Kemnitz, University of Wisconsin – Madison 10:00–10:15 Break 10:15–10:45 Sean Adams, University of Arkansas for Medical Sciences 10:45–11:15 Robert Koza, Maine Medical Center Research Institute 11:15–11:45 Suresh Tyagi, University of Louisville School of Medicine 11:45–12:15 Jacob Selhub, Tufts University Lunch 12:15–1:15 pm Main Dining Room, Biddle Mansion Afternoon Session, moderator: Arthur Cooper, OFAS 1:15–1:45 James Mitchell, Harvard T.H.
    [Show full text]
  • 1 Environmental Factors Shape Methionine Metabolism In
    bioRxiv preprint doi: https://doi.org/10.1101/313288; this version posted May 2, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Environmental factors shape methionine metabolism in p16/MTAP deleted cells Sydney M. Sanderson1, Peter Mikhael1, Ziwei Dai1, and Jason W. Locasale1 1Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA Correspondence: Jason Locasale - [email protected] Abstract The co-deletion of a common tumor suppressor locus and neighboring metabolic gene is an attractive possible synthetic dependency of tumor suppression on metabolism. However, the general impact that these co-deletions have on metabolism, which also dependent on nutrient availability and the tissue of origin, is unknown. As a model to investigate this question, we considered a set of tissue-matched cancer cells with homozygous co-deletions in CDKN2a and MTAP, genes respectively encoding the most commonly deleted tumor suppressor p16 and an enzyme involved in methionine metabolism. A comparative metabolomics analysis revealed that while there exists a definite pan-cancer metabolic signature of MTAP-deletion, this signature was not preserved when cells were subjected to changes in the availability of methionine, serine, or cysteine, nutrients related to methionine metabolism. Notably, the heterogeneity exhibited by these cells in their responsiveness to nutrient availability dominated both MTAP status and tissue-of-origin. Furthermore, re-expression of MTAP exerted a modest effect on metabolism. Together these findings demonstrate that environmental factors, particularly nutrition and tissue identity, may overwhelm the genetic effects of collateral deletions of metabolic genes.
    [Show full text]
  • Strategies for Selective Targeting of the Warburg Effect In
    STRATEGIES FOR SELECTIVE TARGETING OF THE WARBURG EFFECT IN CANCER A Dissertation Presented to the Faculty of the Graduate School of Cornell University In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy by Maria Volpe Liberti December 2018 © 2018 Maria Volpe Liberti STRATEGIES FOR SELECTIVE TARGETING OF THE WARBURG EFFECT IN CANCER Maria Volpe Liberti, Ph.D. Cornell University 2018 Cancer cells undergo numerous adaptive processes to sustain rapid growth and survival. One notable mechanism is by rewiring their metabolism, most prominently through a phenomenon known as the Warburg Effect (WE). The WE is defined as an increase in glucose consumption and lactate secretion in the presence or absence of oxygen. Although the WE has been extensively studied, efforts to therapeutically target it have been largely unsuccessful due to the lack of obvious metabolic biomarkers and difficulties achieving full enzyme inhibition without inducing toxicity in normal tissue . Although targeted cancer therapies that use genetics have been successful, principles for selectively targeting tumor metabolism that also depend on environmental factors remain unknown. This limitation prompted the investigation to determine whether differential control in metabolism can be exploited for therapy. In this dissertation, I first determined whether therapeutic targeting of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), an enzyme that differentially regulates the Warburg Effect in cancer, can result in anti-tumor efficacy. Using comparative metabolomics, integrated pharmacogenomics, and systems biology, I found that koningic acid (KA), a natural product produced by the Trichoderma species, is a highly specific inhibitor of GAPDH. Notably, I determined that the quantitative extent of the Warburg Effect predicts response to KA in both cancer cells and tumors.
    [Show full text]
  • Final Program 79Th Scientific Sessions
    BRIDGING DIABETES RESEARCH WITH GROUNDBREAKING DISCOVERIES scientificsessions.diabetes.org FINALFINAL PPROGRAROGRAMM LIVE: 5.5” X 8.5” TRIM: 6” X 9” BLEED: 6.5” X 9.5” B:6.5” T:6” S:5.5” For adult patients with type 2 diabetes, treated with diet and exercise Learn more at booth #601 B:9.5” S:8.5” T:9” Indication and Limitations of Use Important Safety Information Ozempic® (semaglutide) injection 0.5 mg or 1 mg is WARNING: RISK OF THYROID C-CELL TUMORS indicated as an adjunct to diet and exercise to improve • In rodents, semaglutide causes dose-dependent and treatment- glycemic control in adults with type 2 diabetes mellitus. duration-dependent thyroid C-cell tumors at clinically relevant • Ozempic® is not recommended as a first-line therapy exposures. It is unknown whether Ozempic® causes thyroid C-cell for patients who have inadequate glycemic control on tumors, including medullary thyroid carcinoma (MTC), in humans diet and exercise because of the uncertain relevance as human relevance of semaglutide-induced rodent thyroid C-cell of rodent C-cell tumor findings to humans. tumors has not been determined. • Ozempic® is contraindicated in patients with a personal or family • Ozempic® has not been studied in patients with a history of MTC and in patients with Multiple Endocrine Neoplasia history of pancreatitis. Consider other antidiabetic syndrome type 2 (MEN 2). Counsel patients regarding the therapies in patients with a history of pancreatitis. potential risk for MTC with the use of Ozempic® and inform them ® ® • Ozempic is not a substitute for insulin. Ozempic is of symptoms of thyroid tumors (e.g.
    [Show full text]